[go: up one dir, main page]

ES2171559T3 - Agente para potenciar la actividad del factor de crecimiento nervioso que contiene un derivado de 1,2-etanodiol o una sal del mismo. - Google Patents

Agente para potenciar la actividad del factor de crecimiento nervioso que contiene un derivado de 1,2-etanodiol o una sal del mismo.

Info

Publication number
ES2171559T3
ES2171559T3 ES95934859T ES95934859T ES2171559T3 ES 2171559 T3 ES2171559 T3 ES 2171559T3 ES 95934859 T ES95934859 T ES 95934859T ES 95934859 T ES95934859 T ES 95934859T ES 2171559 T3 ES2171559 T3 ES 2171559T3
Authority
ES
Spain
Prior art keywords
ethanodiol
salt
activity
derivative
potentiate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934859T
Other languages
English (en)
Inventor
Satoshi Ono
Mutsuko Maekawa
Kazunari Hirata
Hirokazu Narita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6284273A external-priority patent/JPH08268883A/ja
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of ES2171559T3 publication Critical patent/ES2171559T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN DERIVADO DE 1,2-ETANODIOL REPRESENTADO POR LA FORMULA GENERAL [I] O SU SAL: TIENE UN EFECTO POTENCIADOR DE ACTIVIDAD NGF Y ES UTIL COMO UN REMEDIO PARA DIFERENTES ENFERMEDADES CAUSADAS POR DEGENERACION DEL SISTEMA NERVIOSO CENTRAL O SISTEMA NERVIOSO PERIFERICO COMO DEMENCIA SENIL DE TIPO ALZHEIMER, COREA DE HUNTINGTON, DIFERENTES NEUROPATIAS, SINDROME DE RILEY-DAY, LESION DEL NERVIO TRAUMATICO, ESCLEROSIS LATERAL AMIOTROFICA (ALS) Y SIMILARES.
ES95934859T 1994-10-25 1995-10-20 Agente para potenciar la actividad del factor de crecimiento nervioso que contiene un derivado de 1,2-etanodiol o una sal del mismo. Expired - Lifetime ES2171559T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6284273A JPH08268883A (ja) 1994-10-25 1994-10-25 １−フェニル−１，２−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤
JP28427294 1994-10-25

Publications (1)

Publication Number Publication Date
ES2171559T3 true ES2171559T3 (es) 2002-09-16

Family

ID=26555404

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95934859T Expired - Lifetime ES2171559T3 (es) 1994-10-25 1995-10-20 Agente para potenciar la actividad del factor de crecimiento nervioso que contiene un derivado de 1,2-etanodiol o una sal del mismo.
ES00100580T Expired - Lifetime ES2208156T3 (es) 1994-10-25 1995-10-20 Un agente para la potenciacion de la actividad del factor del crecimiento del nervio, que contiene 1,2-etanodiol o uno de sus derivados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00100580T Expired - Lifetime ES2208156T3 (es) 1994-10-25 1995-10-20 Un agente para la potenciacion de la actividad del factor del crecimiento del nervio, que contiene 1,2-etanodiol o uno de sus derivados.

Country Status (16)

Country Link
US (6) US5807887A (es)
EP (3) EP1223169A1 (es)
JP (1) JP3218247B2 (es)
KR (1) KR100447738B1 (es)
AU (1) AU700561B2 (es)
CA (1) CA2202032C (es)
CZ (1) CZ293528B6 (es)
DE (2) DE69525063T2 (es)
DK (2) DK0790246T3 (es)
ES (2) ES2171559T3 (es)
HU (1) HU226980B1 (es)
NZ (1) NZ294328A (es)
PL (2) PL187004B1 (es)
RO (1) RO119196B1 (es)
TW (1) TW341570B (es)
WO (1) WO1996012717A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL187004B1 (pl) * 1994-10-25 2004-04-30 Toyama Chemical Co Ltd Nowe pochodne 1,2-etanodiolu oraz kompozycje farmaceutyczne je zawierające
WO1997039740A1 (en) * 1996-04-22 1997-10-30 Toyama Chemical Co., Ltd. Patch containing 1,2-ethanediol derivatives or salts thereof
JP4549452B2 (ja) * 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
AU1506499A (en) * 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
ATE438614T1 (de) 1999-06-11 2009-08-15 Toyama Chemical Co Ltd N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten
AU2001292351B2 (en) * 2000-10-10 2006-02-23 Toyama Chemical Co., Ltd Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
JP4398247B2 (ja) * 2001-10-19 2010-01-13 富山化学工業株式会社 アルキルエーテル誘導体またはその塩
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
PL378582A1 (pl) 2003-03-19 2006-05-02 Biogen Idec Ma Inc. Białko wiążące receptor Nogo
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
EP2205071B1 (en) * 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894058A (en) * 1974-05-17 1975-07-08 Hoechst Co American Tetrahydrobenzofuranylphenoxypropylamines
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JPH05230103A (ja) * 1992-02-18 1993-09-07 Taisho Pharmaceut Co Ltd ガングリオシド化合物
PL187004B1 (pl) * 1994-10-25 2004-04-30 Toyama Chemical Co Ltd Nowe pochodne 1,2-etanodiolu oraz kompozycje farmaceutyczne je zawierające

Also Published As

Publication number Publication date
KR970707114A (ko) 1997-12-01
CA2202032C (en) 2009-06-16
AU3709795A (en) 1996-05-15
DK0790246T3 (da) 2002-03-18
HUT77361A (hu) 1998-03-30
DE69525063D1 (de) 2002-02-21
US6034119A (en) 2000-03-07
EP0790246B1 (en) 2002-01-16
TW341570B (en) 1998-10-01
PL187004B1 (pl) 2004-04-30
EP1020427B1 (en) 2003-10-01
CZ124997A3 (en) 1997-10-15
DE69531877T2 (de) 2004-07-29
CZ293528B6 (cs) 2004-05-12
DE69531877D1 (de) 2003-11-06
WO1996012717A1 (en) 1996-05-02
JP3218247B2 (ja) 2001-10-15
PL187490B1 (pl) 2004-07-30
US5807887A (en) 1998-09-15
ES2208156T3 (es) 2004-06-16
EP1223169A1 (en) 2002-07-17
EP0790246A1 (en) 1997-08-20
EP0790246A4 (en) 1998-03-11
DK1020427T3 (da) 2004-02-09
US5968935A (en) 1999-10-19
US5922721A (en) 1999-07-13
RO119196B1 (ro) 2004-05-28
US5932620A (en) 1999-08-03
CA2202032A1 (en) 1996-05-02
PL319940A1 (en) 1997-09-01
DE69525063T2 (de) 2002-08-14
US6103754A (en) 2000-08-15
KR100447738B1 (ko) 2005-09-20
AU700561B2 (en) 1999-01-07
EP1020427A1 (en) 2000-07-19
NZ294328A (en) 1998-06-26
HU226980B1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
ES2171559T3 (es) Agente para potenciar la actividad del factor de crecimiento nervioso que contiene un derivado de 1,2-etanodiol o una sal del mismo.
ES2061416T3 (es) Ribozimas modificadas.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ES2066120T3 (es) Uso de derivados de bencimidazol como agentes antibacterianos.
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
BR9607565A (pt) Derivados de hidroxilamina úteis para produção de protetores moleculares e sua preparação
ATE280758T1 (de) Mittel zum schutz von nervenzellen
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
BR0016935A (pt) Uso de derivados de ácido fumárico para tratamento de doenças mitocondriais
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
ES2119894T3 (es) Substancia fo-1289 y su produccion.
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
ECSP024400A (es) Derivados de pleuromutilina que tiene actividad antibacteriana
GT199800135A (es) 2 - aminopiridinas con sustituyentes alcoxi ramificados.
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
ES2043957T3 (es) Composicion obtenida a partir de cortezas de arroz y procedimiento para su preparacion.
DE69726143D1 (de) Verwendung von pharmazeutische Zusammensetzungen enthaltend Thymol und/oder Carvacrol in der Behandlung von Histomoniasis
BR9913337A (pt) Derivados tan-1057
BR9815919A (pt) Compostos aza heterocìclicos usados para tratar distúrbios neurológicos e perda de cabelo
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
ES2109683T3 (es) Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b.
ES2095984T3 (es) 2,3-dihidropirano(2,3-b)piridinas aminometil sustituidas, procedimiento para su preparacion y su uso en medicamentos.
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 790246

Country of ref document: ES